 LONDON, April 06, 2021 GLOBE NEWSWIRE -- Achilles Therapeutics plc NASDAQ: ACHL, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the closing of its previously announced initial public offering in the United States of 9,750,000 American Depositary Shares ADSs representing 9,750,000 ordinary shares, at an initial public offering price of 18.00 per ADS. The gross proceeds to Achilles from the offering were approximately 175.5 million. All ADSs sold in the offering were offered by Achilles. 